Download by
Scanning QR Code
No Stock Yet
Huaxi Securities: Continued optimism about domestic CXO sentiment based on engineer dividends and industrial cost advantages
The Zhitong Finance App learned that Huaxi Securities released a research report saying that it comprehensively analyzed overseas investment and financing data and the global TOP15 R&D investment situation, as well as the increase in operating income, orders, number of employees and capital expenditure of overseas CXO companies in 22, maintained an early judgment on the prosperity of the overseas CXO industry, based on domestic engineer dividends and industrial cost advantages, and continues to recommend the pharmaceutical company Ming Kangde (603259.SH), Jiuzhou Pharmaceutical (603456.SH), Sunshine Nuohe (), and Baicheng 688621.SH Pharmaceuticals (301096
The Total Return for Zhejiang Jiuzhou Pharmaceutical (SHSE:603456) Investors Has Risen Faster Than Earnings Growth Over the Last Five Years
Zhejiang Jiuzhou Pharmaceutical Co., Ltd (SHSE:603456) shareholders might be concerned after seeing the share price drop 13% in the last month. But that doesn't change the fact that shareholders ha
Jiuzhou Pharmaceutical (603456.SH) plans to set up a partnership of 15 million yuan to invest in shares of unlisted company Xihua Testing
Gelonhui March 14 丨 Jiuzhou Pharmaceutical (603456.SH) announced that on March 13, 2023, Hongzhou Investment, a wholly-owned subsidiary of the company, and Ningbo Jundu Private Equity Fund Management Co., Ltd. (“Kundu Management”), Ningbo Jiefeng Hongming Venture Capital Partnership (Limited Partnership) (known as “Jiefeng Investment”), Huang Xiqiang, Zhang Ning, Gan Quan and Huang Yong signed the “Ningbo Jundu Jingming Venture Capital Partnership (Limited Partnership)” to jointly invest in Ningbo Jundu Jingming Venture Capital Partnership (Limited Partnership). The total investment pledged by the partnership is RMB 55.1 million (including this investment)
Jiuzhou Pharmaceutical (603456.SH) plans to acquire 100% of Ruihua Zhongshan's shares for 15.1 million US dollars
Gelonhui, March 12, 丨 Jiuzhou Pharmaceutical (603456.SH) announced that in order to further enhance the company's CDMO formulation business acceptance capacity and accelerate the implementation process of the company's “AP+formulation” integrated platform construction strategy, the company held the 22nd meeting of the 7th board of directors and the 16th meeting of the 7th board of supervisors on September 26, 2022. The meeting deliberated and passed the “Proposal on Changing the Use of Part of the Funds Raised in the Funding Project to Acquire 100% of the Shares of Zhongshan Pharmaceutical Factory belonging to Sandeshi (China)”, agreeing to the company's use of “Zhejiang Siwei Pharmaceutical” Technology Co., Ltd. CDMO
Jiuzhou Pharmaceutical (603456.SH): It has spent a total of about 61.012 million yuan to repurchase 1,604,500 shares
Gelonghui, March 12, 丨 Jiuzhou Pharmaceutical (603456.SH) announced that as of March 10, 2023, the company had repurchased a total of 1,604,500 shares through centralized bidding transactions. The share repurchased accounted for 0.18% of the company's total share capital. The highest transaction price was 40.96 yuan/share, the lowest price was 35.06 yuan/share, and the total amount paid was about 61.012 million yuan (excluding transaction fees).
Jiuzhou Pharmaceutical (603456) Company Research Report: Binding Novartis to Successfully Transforming CDMO to Accelerate Production Capacity Building, Optimistic about the Company's Future Rapid Development of “AP+Formulation” Integrated CDMO
Looking at the past, cut into Novartis's supply chain and complete the CDMO strategy transformation. The in-depth cooperation with Novartis drove the rapid development of Jiuzhou Pharmaceutical's CDMO business in 2018-2021, verified the company's world-class CDMO capabilities, and entered the global standardized market supply chain system. The scarcity of platforms and the pioneering acceptance of subsequent domestic orders laid the foundation for our understanding of the company's accelerated development. Looking at the present, equity incentives bind the core backbone, and raise additional capital to speed up production capacity construction. Since 2017, the company has implemented equity incentives 4 times, “2022 Restricted Stock Incentive Plan (Draft)
Jiuzhou Pharmaceutical (603456.SH) has repurchased a total of 1,604,500 shares at a cost of 61 million yuan
According to the Zhitong Finance App, Jiuzhou Pharmaceutical (603456.SH) issued an announcement. As of February 28, the company had repurchased a total of 1,604,500 shares through centralized bidding transactions. The share repurchased accounted for 0.18% of the company's total share capital. The highest transaction price was 40.96 yuan/share, the lowest price was 35.06 yuan/share, and the total amount paid was 61 million yuan.
With EPS Growth And More, Zhejiang Jiuzhou Pharmaceutical (SHSE:603456) Makes An Interesting Case
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even companies that have no revenue, no profit, and a record of falling short, can manage
Jiuzhou Pharmaceutical (603456.SH): No repurchase was implemented in January
Gelonghui, Feb. 1 丨 Jiuzhou Pharmaceutical (603456.SH) announced that in January 2023, the company did not implement a repurchase. As of January 31, 2023, the company has repurchased a total of 1,2573 million shares through centralized bidding transactions. The repurchased shares accounted for 0.14% of the company's total share capital. The highest transaction price was 40.96 yuan/share, the lowest price was 35.06 yuan/share, and the total amount paid was 47.2965 million yuan (excluding transaction fees).
Jiuzhou Pharma Nets 2.5 Billion Yuan From Share Placement
06:50 AM EST, 01/26/2023 (MT Newswires) -- Jiuzhou Pharmaceutical (SHA:603456) has raised 2.49 billion yuan in net proceeds from a private share placement, according to a filing on Thursday. The Chine
Loading...
No Stock Yet